SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Zeev Hed who wrote (111)2/24/1997 7:03:00 PM
From: David B. Higgs   of 371
 
I am considering purchasing Immunomedics but my medical and FDA approval procedures knowledge is very week. If LeukoScan is in the first stages of FDA Phase III testing, when can we expect results to be reported. I seem to remember from a small bio-tech that I owned years ago, that there are two cycles of Phase III testing that could last up to a year each. Does this seem reasonable? If so, would this mean that LeukoScan would not factor in to stock value over the next six months?

I noted comments in this thread questioning Mallinqkrodt's marketing of CEA-Scan. I've heard a rummor that IMMU is talking to Bristol-Myers Squidd (sp?) as a partner for European marketing of LeukoScan. If this were true, any guess on what short term impact this would have share price?

Regards
Dave
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News